Name: Bone Biologics Corporation (BBLG) Financial Statements
Creator: FinSpry

Bone Biologics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Bone Biologics Corporation income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	2.13	6.91	1.58	0.08	0.34
Selling, General & Administrative	2.09	2.52	2.09	1.02	0.48
Operating Expenses	4.22	9.43	3.67	1.10	0.83
Operating Income	-4.22	-9.43	-3.67	-1.10	-0.83
Other Income/Expense
Interest Income	0.06	0.00	0.00	0.00	0.00
Interest Expense	0.00	0.00	-0.73	-0.81	-1.00
Other Income/Expense	0.11	0.89	2.91	0.30	0.00
Income
Income Before Tax	-4.11	-8.95	-1.48	-1.61	-1.82
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	-4.11	-8.95	-1.48	-1.61	-1.82
Net Income - Continuous Operations	-4.11	-8.95	-1.48	-1.61	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	0.11	-9.43	-3.67	-0.81	-0.82
EBIT	-4.22	-9.43	-3.67	-1.10	-0.83
Depreciation & Amortization	4.22	0.00	0.00	0.00	0.00
Earnings Per Share
Basic EPS	-5.00	-204.00	-187.00	-504.00	-
Diluted EPS	-5.00	-204.00	-187.00	-504.00	-
Basic Shares Outstanding	1.52	0.04	0.01	0.00	0.00
Diluted Shares Outstanding	1.52	0.04	0.01	0.00	0.00